Y's Therapeutics, Inc.
🇺🇸United States
YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation
Phase 2
- Conditions
- Ischemia Reperfusion Injury
- Interventions
- Drug: recombinant P-selectin glycoprotein ligand Ig fusion proteinDrug: Viaspan® and saline
- First Posted Date
- 2009-04-07
- Last Posted Date
- 2009-04-07
- Lead Sponsor
- Y's Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00876902
- Locations
- 🇺🇸
UCLA School of Medicine, Los Angeles, California, United States
YSPSL for Prevention of Delayed Graft Function in Cadaveric Liver Transplantation
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2008-01-29
- Lead Sponsor
- Y's Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00450398
- Locations
- 🇺🇸
UCLA School of Medicine, Los Angeles, California, United States
YSPSL for Prevention of Delayed Graft Function Part A
Completed
- Conditions
- Delayed Graft Function
- First Posted Date
- 2006-03-01
- Last Posted Date
- 2008-01-29
- Lead Sponsor
- Y's Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00298181
- Locations
- 🇺🇸
Baylor University Medical Center Transplantation Services, Dallas, Texas, United States
🇺🇸Methodist Healthcare University Hospital, Memphis, Tennessee, United States
🇺🇸Westchester Medical Center, New York Medical College, Hawthorne, New York, United States
YSPSL for Prevention of Delayed Graft Function Part B
- First Posted Date
- 2006-03-01
- Last Posted Date
- 2008-01-29
- Lead Sponsor
- Y's Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00298168
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Baylor University Medical Center Transplantation Services, Dallas, Texas, United States
🇺🇸University of Texas, Organ Transplantation, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath